AXSM

In a report released on November 7, Marc Goodman from SVB Securities maintained a Buy rating on Axsome Therapeutics (AXSM - Research Report), with a price target of $65.00. The company's shares closed yesterday at $59.02.Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Axsome Therapeutics, and Biogen. According to TipRanks, Goodman has an average return of -1.0% and a 41.53% success rate on recommended stocks. In addition to SVB Securities, Axsome Therapeutics also received a Buy from Cantor Fitzgerald's Charles Duncan in a report issued on November 8. However, on the same day, Morgan Stanley maintained a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).
https://www.tipranks.com/news/blurbs/svb-securities-reaffirms-their-buy-rating-on-axsome-therapeutics-axsm?utm_source=advfn.com&utm_medium=referral